基于人乳头瘤病毒的宫颈筛查与长期宫颈癌风险:瑞典一项随机卫生保健政策试验
在瑞典首都地区组织的宫颈筛查项目中,395 725名30-64岁合格女性于2014-16年被随机分配至HPV筛查或细胞学筛查政策,随访8年比较浸润性宫颈癌发病率。意向筛查分析显示HPV组浸润性宫颈癌风险较细胞学组低17%(HR 0.83,95%CI 0.70-0.98),符合方案分析低28%(HR 0.72,95%CI 0.54-0.95)。HPV筛查组阴道镜活检转诊数更高。
要点
- 随机政策试验中,受邀HPV筛查女性浸润性宫颈癌风险较受邀细胞学筛查低17%(HR 0.83,95%CI 0.70-0.98)。
- 实际参与HPV筛查女性浸润性宫颈癌风险较参与细胞学筛查低28%(HR 0.72,95%CI 0.54-0.95)。
- 基线HPV阴性女性8年浸润性宫颈癌风险为1.3/10万 person-years(95%CI 0.6-2.4),正常细胞学为9.1/10万 person-years(95%CI 6.7-11.8)。
核心结论
- 该随机政策试验发现,在真实世界环境中基于HPV的筛查在预防浸润性宫颈癌方面优于细胞学筛查。
- 单次基线HPV阴性检测与8年后极低的浸润性宫颈癌风险相关。
- 然而,HPV阳性且细胞学分流阴性者与高浸润性宫颈癌风险相关。
研究设计与样本
- 瑞典首都地区组织的宫颈筛查项目邀请所有30-64岁合格女性参加HPV筛查对比细胞学筛查的随机卫生保健政策试验。
- 2014-16年,395 725名合格女性被非 conceal 随机分配至两种筛查政策,比较8年随访期间的浸润性宫颈癌发病率。
- 意向筛查分析纳入所有受邀女性,符合方案分析纳入按方案参加基线筛查的女性;试验注册号ClinicalTrials.gov NCT01511328。
主要发现
- 受邀HPV筛查女性浸润性宫颈癌风险较受邀细胞学筛查女性低17%(HR 0.83,95%CI 0.70-0.98)。
- 参与HPV筛查女性浸润性宫颈癌风险较参与细胞学筛查女性低28%(HR 0.72,95%CI 0.54-0.95)。
- HPV政策组阴道镜活检转诊数在意向筛查分析中为15 832/212 199(7.5%),符合方案基线分析中为9968/110 176(9.0%);细胞学政策组分别为12 650/183 120(6.9%)和7179/90 821(7.9%)。
- 基线HPV阴性女性浸润性宫颈癌风险为1.3/10万 person-years(95%CI 0.6-2.4),正常细胞学女性为9.1/10万 person-years(95%CI 6.7-11.8)。
- HPV阳性且细胞学分流阴性女性浸润性宫颈癌风险为79.2/10万 person-years,HPV 16或18阳性且细胞学分流阴性女性为318.2/10万 person-years。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV)-based cervical screening is a globally recommended public health policy. Randomised clinical trials find superior performance of primary HPV-based screening compared with cytology for preventing cervical cancer. However, additional evidence from real-world public health policies is needed. In preplanned secondary analysis of a randomised health-care policy trial in Sweden we aimed to evaluate which policy provided better protection against invasive cervical cancer, after two full rounds of screening. METHODS: The organised cervical screening programme in the capital region of Sweden invited all women aged 30-64 years and eligible for screening to a randomised health-care policy trial of HPV-based versus cytology-based screening. During 2014-16, 395 725 eligible women were randomly assigned (non-concealed) to either policy and the invasive cervical cancer incidences over 8 years of follow-up were compared. Intention-to-screen analyses included all invited women and per-protocol analyses the women that attended baseline screening according to protocol. This trial is registered with ClinicalTrials.gov, NCT01511328. FINDINGS: Women invited to HPV-based cervical screening had a 17% lower invasive cervical cancer risk compared with women invited to cytology (hazard ratio [HR] 0·83, 95% CI 0·70-0·98). Women participating in HPV-based screening had a 28% lower invasive cervical cancer risk compared with women participating with cytology (HR 0·72, 95% CI 0·54-0·95). Adverse events were a higher number of referrals to colposcopy with biopsy in the HPV policy (15 832 [7·5%] of 212 199 in intention to screen analyses and 9968 [9·0%] of 110 176 per protocol at baseline) than in the cytology policy (12 650 [6·9%] of 183 120 in intention to screen analyses, and 7179 [7·9%] of 90 821 per protocol at baseline). Women who were HPV-negative at baseline had invasive cervical cancer risks of 1·3 (95% CI 0·6-2·4) per 100 000 person-years, whereas the risk for women with normal cytology was 9·1 (6·7-11·8) per 100 000 person-years. HPV-positive women with negative cytology triage had invasive cervical cancer risks of 79·2 per 100 000 person-years and HPV 16 or HPV 18-positive women with negative cytology triage had risks of 318·2 per 100 000 person-years. INTERPRETATION: This randomised policy trial found HPV-based screening to be superior for preventing invasive cervical cancer in the real-world setting. A single baseline HPV-negative test was associated with a very low invasive cervical cancer risk after 8 years. However, HPV positivity with negative cytology triage was associated with high invasive cervical cancer risks. FUNDING: Region Stockholm, Swedish Cancer Society, and European Union Horizon 2020.
引用
- Wang J, Elfström KM, Dillner J, et al. Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden. Lancet Public Health. 2024. PMID: 39486904. doi:10.1016/S2468-2667(24)00218-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。